ACC 2026: Post-TAVR treatments show potential in reducing cardiovascular risks
At the American College of Cardiology (ACC) 2026 in New Orleans, retrospective results were presented demonstrating the possibility of using…
Analyst Comment
Epic secures a £222m federated EPR contract across Somerset and Dorset
Knight Therapeutics advances chronic GvHD expansion strategy
JPM26: Ypsomed commits to self-care delivery devices in new strategic plan
JPM26: Opus Genetics builds momentum in rare retinal gene therapy
JPM26: Butterfly Network aims to close the global medical imaging gap
JPM26: Rakuten Medical unveils transformative photoimmunotherapy platform
JPM26: ICU Medical hopeful to ‘get out of the woods’ soon
